South African study reveals early-onset HFpEF driven by arterial stiffness, not age

In South Africa, a disease long thought to strike the elderly is arriving decades early. Researchers studying 351 Black South Africans—95 with heart failure and preserved ejection fraction (HFpEF) and 256 without—found that the condition was appearing in people around 58 years old, predominantly women, most of them overweight or obese, all of them dealing with high blood pressure. This is not the HFpEF of developed countries, where it typically affects people in their seventies and eighties. Something different is happening here, and the culprit appears to be the stiffening of arteries rather than the simple passage of time.

Hypertension affects roughly 30 percent of Africans, and in South Africa it remains the leading risk factor for cardiovascular death. The country's rapid urbanization, dietary shifts, and sedentary patterns have accelerated the problem. What makes this new finding striking is not just that younger people are developing HFpEF, but that they are doing so in a way that looks mechanically distinct from what clinicians see in older patients elsewhere. The researchers measured pulse wave velocity—essentially how fast pressure waves travel through the arteries—and found a dramatic difference. Those with HFpEF had stiffer arteries (10.9 meters per second) compared to hypertensive controls without HFpEF (6.9 meters per second). That gap, statistically significant and clinically meaningful, suggested that premature vascular aging, not chronological age, was the driving force.

The heart responds to chronic high blood pressure by thickening its walls. But the pattern of thickening differed sharply between the two groups. Among those with HFpEF, 73 percent showed concentric left ventricular hypertrophy—the heart wall thickened uniformly, the chamber squeezed inward, the muscle stiffened. Among hypertensive controls without HFpEF, the pattern was different: 45 percent had normal heart geometry, and among those who did develop thickening, eccentric hypertrophy (where the chamber dilates alongside wall thickening) was more common than concentric. This distinction matters. Concentric remodeling reflects pure pressure overload—the heart working against relentless resistance. Eccentric remodeling often reflects volume stress, suggesting a different underlying injury.

The inflammatory markers told a complementary story. Galectin-3, a protein associated with fibrosis and tissue remodeling, was significantly elevated in those with HFpEF. C-reactive protein, a marker of systemic inflammation, was higher. Heart rate was faster. Kidney function was declining in 27.5 percent of HFpEF participants—a sign of end-organ damage from years of uncontrolled or inadequately controlled pressure. One quarter of the HFpEF group had stage 3 chronic kidney disease, compared to virtually none of the controls. The body was paying a price.

What made the findings more troubling was that despite treatment, the problem persisted. Most HFpEF patients were taking diuretics (77 percent), ACE inhibitors (63 percent), and calcium channel blockers (40 percent)—often in combination. Yet their blood pressure remained elevated, their arteries remained stiff, and their hearts remained remodeled. The control group, by contrast, received less intensive treatment and showed better blood pressure control. This suggested that the HFpEF group's disease was not simply undertreated hypertension; it was something more resistant, more deeply rooted in vascular and cardiac structure.

One puzzle emerged from the biomarkers. NT-proBNP, a hormone released by stressed heart tissue and typically elevated in heart failure, was surprisingly low in this cohort—below diagnostic thresholds despite clear clinical symptoms and echocardiographic evidence of dysfunction. The researchers attributed this to obesity, which suppresses natriuretic peptide levels through multiple mechanisms: enhanced clearance by fat tissue, reduced myocardial wall stress from epicardial fat deposition, and impaired hormone synthesis from insulin resistance. This finding carries practical weight: it means that standard diagnostic cutoffs for heart failure may miss younger, obese patients in sub-Saharan Africa, requiring clinicians to rely more heavily on symptoms, imaging, and structural evidence than on blood tests alone.

The study was cross-sectional, meaning it captured a moment in time rather than tracking people forward. The researchers could not prove that arterial stiffness causes HFpEF, only that the two travel together. But the pattern was coherent: younger, obese, hypertensive Black South Africans with the stiffest arteries and the most concentric heart remodeling were the ones developing HFpEF. Those without HFpEF, despite similar age and obesity, had more compliant arteries and different patterns of heart adaptation. The implication was clear: vascular aging, not calendar age, was the engine driving early-onset heart failure in this population. Current antihypertensive regimens, effective at lowering blood pressure numbers, were not fully addressing the underlying arterial stiffness or preventing the cascade of remodeling that leads to diastolic dysfunction. New approaches—ones that target vascular compliance directly—may be needed to interrupt this trajectory before it reaches the point of symptomatic heart failure.